Research Article
BibTex RIS Cite

Can ischemia modified albumin (IMA) and total sulfhydryl level (TSH) be used as a biomarker in the diagnosis of bladder tumor? A prospective case-control study

Year 2020, Volume: 4 Issue: 12, 1104 - 1107, 01.12.2020
https://doi.org/10.28982/josam.820913

Abstract

Aim: Bladder tumor is one of the most common cancers. Cystoscopy, which is an invasive procedure, is used in its diagnosis. We conducted a study to determine whether a more non-invasive method can be used for this purpose. In this study, the uses of Ischemia Modified Albumin (IMA) and total sulfhydryl level (TSH), which are both antioxidant markers, were investigated for the diagnosis of bladder tumor.
Methods: Ischemia Modified Albumin (IMA) and total sulfhydryl level (TSH) were identified by the spectrophotometric method. Patients with primary bladder tumors who did not receive any prior treatments or undergo any interventions were included in this prospective case control study. Those with severe cardiac and neurological diseases, other malignancies, acute and chronic infectious diseases, active organ failure, chronic obstructive pulmonary diseases, and other ischemic immunosuppressive diseases, along with individuals with severely low or high serum albumin levels (<20 or >55 g/L) were excluded from the study.
Results: Forty-two primary bladder tumors and 45 healthy volunteers were included in the study. Serum IMA and TSH levels of the patient and control groups were compared. Patients with bladder tumors had high serum IMA (P=0.045) levels and low TSH levels (P=0.033).
Conclusion: Both IMA and total TSH can be considered non-invasive biomarkers in the diagnosis of bladder tumor. Since there are few studies on this subject in the literature, further, larger studies are needed.

Thanks

if you fast track my manuscript I will be happy

References

  • 1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. European Urology. 2017;71(1):96–108.
  • 2. Sawicka E, Kratz EM, Szymańska B, Guzik A, Wesołowski A, Kowal P, et al. Preliminary Study on Selected Markers of Oxidative Stress, Inflammation and Angiogenesis in Patients with Bladder Cancer. Pathol Oncol Res. 2019 Mar 4. doi: 10.1007/s12253-019-00620-5.
  • 3. Awadallah SM, Atoum MF, Nimer NA. Ischemia modified albumin: an oxidative stress marker in beta-thalassemia major. Clin Chim Acta 2012; 413(9-10):907-10.
  • 4. Uzar E, Tamam Y, Evliyaoglu O, Tuzcu A, Beyaz C, Acar A, et al. Serum prolidase activity and oxidative status in patients with diabetic neuropathy. Neurol Sci. 2012;33(4):875-80.
  • 5. Chawla R, Goyal N, Calton R, Goyal S. Ischemia modified albumin: A novel marker for acute coronary syndrome. Indian J Clin Biochem. 2006;21:77-82.
  • 6. Lee E, Eom JE, Jeon KH, Kim TH, Kim E, Jhon GJ, et al. Evaluation of albumin structural modifications through cobalt-albumin binding (CAB) assay. J Pharm Biomed Anal. 2014;91:17-23.
  • 7. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes review and clinical implications. Clin Chem Lab Med 2011;49:177-84.
  • 8. Zurawska-Płaksej E, Grzebyk E, Marciniak D, Szymańska-Chabowska A, Piwowar A. Oxidatively modified forms of albumin in patients with risk factors of metabolic syndrome. J Endocrinol Invest. 2014;37:819-27.
  • 9. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med. 2011; 49(2):177-84.
  • 10. Cakir M, Karahan SC, Mentese A, Sag E, Cobanoglu U, Polat TB, et al. Ischemia modified albumin levels in children with chronic liver disease. Gut Liver 2012;6(1):92-7.
  • 11. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Meîhod Enzymol. 233:380(S994).
  • 12. Stockcr R, Frei B. Endogenous antioxidant defences İn human blood plasma,"Oxidative Stress: Oxidants and Antioxidants, editör: Sies H, Acedemic Press, London (1991):213.
  • 13. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160:1–40.
  • 14. Islam MO, Bacchetti T, Ferretti G. Alterations of Antioxidant Enzymes and Biomarkers of Nitro-oxidative Stress in Tissues of Bladder Cancer. Oxid Med Cell Longev. 2019 May 5;2019:2730896. doi: 10.1155/2019/2730896. eCollection 2019
  • 15. Huang QX, Ma J, Wang YS. Significance of preoperative ischemia-modified albumin in operable and advanced gastric cancer. Cancer Biomark. 2018;22(3):477-85.
  • 16. Erkut N, Mentese A, Ozbas HM, Sumer A, Orem A, Topbas M, et al. The indicator of hypoxia in acute leukemia: Ischemia-modified albumin. Cancer Biomark. 2015;15(5):559-65.
  • 17. Da Silveira RA, Hermes CL, Almeida TC, Bochi GV, De Bona KS, Moretto MB. et al. Ischemia-modified albumin and inflammatory biomarkers in patients with prostate cancer Clin Lab. 2014;60(10):1703-8.
  • 18. Ellidag HY, Eren E, Aydin O, Akgol E, Yalcinkaya S, Sezer C, et al. Ischemia modified albumin levels and oxidative stress in patients with bladder cancer Asian Pac J Cancer Prev. 2013;14(5):2759-63.
  • 19. Wong R, Rosser CJ. UroSEEK gene panel for bladder cancer surveillance Transl Androl Urol. 2019 Dec;8(Suppl 5):S546-9.
  • 20. Ryrfeldt A, Bannenberg G, Moldeus P. Free radicals and lung disease. British Med Bull. 1993;49(3):588-603.
  • 21. Cotgreave IA, Johansson U, Moldeus P, Brattsand R. The effect of acute cigarette smoke inhalation on pulmonary and systemic cysteine and glutathione redox states in the rat. Toxicology. 1987;45:203-12.

İskemi modifiye albümin (İMA) ve toplam sülfhidril seviyesi (TSH) mesane tümörü tanısında biyobelirteç olarak kullanılabilir mi? İleriye dönük vaka kontrol çalışması

Year 2020, Volume: 4 Issue: 12, 1104 - 1107, 01.12.2020
https://doi.org/10.28982/josam.820913

Abstract

Amaç: Mesane tümörü en yaygın görülen kanserlerden biridir.Tanısında sistoskopi gibi invazif bir yöntem kullanılmaktadır.Bu çalışmada, mesane tümörü tanısında kulanılmak üzere daha non invaziv bir yöntem belirlemek için bir oksidan belirteç olan İskemi Modifiye Albümin (İMA) ve yeni bir antioksidan belirteç olan total sülfhidril (TSH) düzeyinin mesane tümörlü hastalarda bir biyobelirteç olup olamayacağını araştırmayı amaçladık.
Yöntemler: İskemik Modifiye Albümin (İMA) ve total sülfhidril seviyesi (TSH) spektrofotometrik yöntemle belirlendi. Çalışmaya, primer mesane tümörü olan ve daha önce herhangi bir tedavi almayan aynı zamanda herhangi bir cerrahi müdahalesi olmayan hastalar dahil edilirken, ağır kalp ve nörolojik hastalıkları, diğer maligniteleri, akut ve kronik enfeksiyon hastalıkları, aktif organ yetmezliği, kronik obstrüktif akciğer hastalığı olan ve diğer iskemik immünsüpresif hastalıkları olan hastalar çalışma dışı bırakıldı. Ciddi derecede düşük veya yüksek serum albumin seviyeleri (<20 veya >55 g/L) olan kişiler de çalışmadan çıkarıldı.
Bulgular: 42 primer mesane tümörü ve 45 sağlıklı gönüllü çalışmaya dahil edildi. Hasta ve gönüllü gruplarının serum İMA ve total TSH düzeyleri karşılaştırıldı. Kontrol grubuna göre mesane tümörü olan hastaların serum İMA (P=0,045) düzeyleri yüksek ve total TSH düzeyleri düşük (P=0,033) izlendi.
Sonuç: Hem İMA hemde Total TSH düzeyi, mesane tümörü tanısında daha noninvaziv bir biyobelirteç olarak düşünülebilir. Literatürde bu konuda çok fazla çalışma bulunmadığından daha geniş çaplı çalışmalara ihtiyaç vardır.

References

  • 1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. European Urology. 2017;71(1):96–108.
  • 2. Sawicka E, Kratz EM, Szymańska B, Guzik A, Wesołowski A, Kowal P, et al. Preliminary Study on Selected Markers of Oxidative Stress, Inflammation and Angiogenesis in Patients with Bladder Cancer. Pathol Oncol Res. 2019 Mar 4. doi: 10.1007/s12253-019-00620-5.
  • 3. Awadallah SM, Atoum MF, Nimer NA. Ischemia modified albumin: an oxidative stress marker in beta-thalassemia major. Clin Chim Acta 2012; 413(9-10):907-10.
  • 4. Uzar E, Tamam Y, Evliyaoglu O, Tuzcu A, Beyaz C, Acar A, et al. Serum prolidase activity and oxidative status in patients with diabetic neuropathy. Neurol Sci. 2012;33(4):875-80.
  • 5. Chawla R, Goyal N, Calton R, Goyal S. Ischemia modified albumin: A novel marker for acute coronary syndrome. Indian J Clin Biochem. 2006;21:77-82.
  • 6. Lee E, Eom JE, Jeon KH, Kim TH, Kim E, Jhon GJ, et al. Evaluation of albumin structural modifications through cobalt-albumin binding (CAB) assay. J Pharm Biomed Anal. 2014;91:17-23.
  • 7. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes review and clinical implications. Clin Chem Lab Med 2011;49:177-84.
  • 8. Zurawska-Płaksej E, Grzebyk E, Marciniak D, Szymańska-Chabowska A, Piwowar A. Oxidatively modified forms of albumin in patients with risk factors of metabolic syndrome. J Endocrinol Invest. 2014;37:819-27.
  • 9. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med. 2011; 49(2):177-84.
  • 10. Cakir M, Karahan SC, Mentese A, Sag E, Cobanoglu U, Polat TB, et al. Ischemia modified albumin levels in children with chronic liver disease. Gut Liver 2012;6(1):92-7.
  • 11. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Meîhod Enzymol. 233:380(S994).
  • 12. Stockcr R, Frei B. Endogenous antioxidant defences İn human blood plasma,"Oxidative Stress: Oxidants and Antioxidants, editör: Sies H, Acedemic Press, London (1991):213.
  • 13. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160:1–40.
  • 14. Islam MO, Bacchetti T, Ferretti G. Alterations of Antioxidant Enzymes and Biomarkers of Nitro-oxidative Stress in Tissues of Bladder Cancer. Oxid Med Cell Longev. 2019 May 5;2019:2730896. doi: 10.1155/2019/2730896. eCollection 2019
  • 15. Huang QX, Ma J, Wang YS. Significance of preoperative ischemia-modified albumin in operable and advanced gastric cancer. Cancer Biomark. 2018;22(3):477-85.
  • 16. Erkut N, Mentese A, Ozbas HM, Sumer A, Orem A, Topbas M, et al. The indicator of hypoxia in acute leukemia: Ischemia-modified albumin. Cancer Biomark. 2015;15(5):559-65.
  • 17. Da Silveira RA, Hermes CL, Almeida TC, Bochi GV, De Bona KS, Moretto MB. et al. Ischemia-modified albumin and inflammatory biomarkers in patients with prostate cancer Clin Lab. 2014;60(10):1703-8.
  • 18. Ellidag HY, Eren E, Aydin O, Akgol E, Yalcinkaya S, Sezer C, et al. Ischemia modified albumin levels and oxidative stress in patients with bladder cancer Asian Pac J Cancer Prev. 2013;14(5):2759-63.
  • 19. Wong R, Rosser CJ. UroSEEK gene panel for bladder cancer surveillance Transl Androl Urol. 2019 Dec;8(Suppl 5):S546-9.
  • 20. Ryrfeldt A, Bannenberg G, Moldeus P. Free radicals and lung disease. British Med Bull. 1993;49(3):588-603.
  • 21. Cotgreave IA, Johansson U, Moldeus P, Brattsand R. The effect of acute cigarette smoke inhalation on pulmonary and systemic cysteine and glutathione redox states in the rat. Toxicology. 1987;45:203-12.
There are 21 citations in total.

Details

Primary Language English
Subjects Urology
Journal Section Research article
Authors

Recep Eryılmaz 0000-0002-4506-8784

Canan Demir 0000-0002-4204-9756

Rahmi Aslan 0000-0002-4563-0386

Halit Demir 0000-0002-2746-7941

Kerem Taken 0000-0002-4370-4222

Publication Date December 1, 2020
Published in Issue Year 2020 Volume: 4 Issue: 12

Cite

APA Eryılmaz, R., Demir, C., Aslan, R., Demir, H., et al. (2020). Can ischemia modified albumin (IMA) and total sulfhydryl level (TSH) be used as a biomarker in the diagnosis of bladder tumor? A prospective case-control study. Journal of Surgery and Medicine, 4(12), 1104-1107. https://doi.org/10.28982/josam.820913
AMA Eryılmaz R, Demir C, Aslan R, Demir H, Taken K. Can ischemia modified albumin (IMA) and total sulfhydryl level (TSH) be used as a biomarker in the diagnosis of bladder tumor? A prospective case-control study. J Surg Med. December 2020;4(12):1104-1107. doi:10.28982/josam.820913
Chicago Eryılmaz, Recep, Canan Demir, Rahmi Aslan, Halit Demir, and Kerem Taken. “Can Ischemia Modified Albumin (IMA) and Total Sulfhydryl Level (TSH) Be Used As a Biomarker in the Diagnosis of Bladder Tumor? A Prospective Case-Control Study”. Journal of Surgery and Medicine 4, no. 12 (December 2020): 1104-7. https://doi.org/10.28982/josam.820913.
EndNote Eryılmaz R, Demir C, Aslan R, Demir H, Taken K (December 1, 2020) Can ischemia modified albumin (IMA) and total sulfhydryl level (TSH) be used as a biomarker in the diagnosis of bladder tumor? A prospective case-control study. Journal of Surgery and Medicine 4 12 1104–1107.
IEEE R. Eryılmaz, C. Demir, R. Aslan, H. Demir, and K. Taken, “Can ischemia modified albumin (IMA) and total sulfhydryl level (TSH) be used as a biomarker in the diagnosis of bladder tumor? A prospective case-control study”, J Surg Med, vol. 4, no. 12, pp. 1104–1107, 2020, doi: 10.28982/josam.820913.
ISNAD Eryılmaz, Recep et al. “Can Ischemia Modified Albumin (IMA) and Total Sulfhydryl Level (TSH) Be Used As a Biomarker in the Diagnosis of Bladder Tumor? A Prospective Case-Control Study”. Journal of Surgery and Medicine 4/12 (December 2020), 1104-1107. https://doi.org/10.28982/josam.820913.
JAMA Eryılmaz R, Demir C, Aslan R, Demir H, Taken K. Can ischemia modified albumin (IMA) and total sulfhydryl level (TSH) be used as a biomarker in the diagnosis of bladder tumor? A prospective case-control study. J Surg Med. 2020;4:1104–1107.
MLA Eryılmaz, Recep et al. “Can Ischemia Modified Albumin (IMA) and Total Sulfhydryl Level (TSH) Be Used As a Biomarker in the Diagnosis of Bladder Tumor? A Prospective Case-Control Study”. Journal of Surgery and Medicine, vol. 4, no. 12, 2020, pp. 1104-7, doi:10.28982/josam.820913.
Vancouver Eryılmaz R, Demir C, Aslan R, Demir H, Taken K. Can ischemia modified albumin (IMA) and total sulfhydryl level (TSH) be used as a biomarker in the diagnosis of bladder tumor? A prospective case-control study. J Surg Med. 2020;4(12):1104-7.